Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

Relationship between sigma-1 receptor availability and depressive or cognitive symptoms in acute early onset unipolar depression: a (S)-(-)-[18F]Fluspidine PET investigation

Philipp Meyer, Maria Strauss, Georg Becker, Swen Hesse, Klara Bednasch, Barbara Ettrich, Franziska Zientek, Michael Rullmann, Julia Luthardt, Steffen Fischer, Marianne Patt, Barthel Henryk, Bernhard Wunsch, Peter Brust and Osama Sabri
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 106;
Philipp Meyer
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Strauss
2Department of Psychiatry and Psychotherapy, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georg Becker
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Swen Hesse
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klara Bednasch
2Department of Psychiatry and Psychotherapy, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Ettrich
2Department of Psychiatry and Psychotherapy, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franziska Zientek
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Rullmann
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Luthardt
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffen Fischer
3Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Patt
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barthel Henryk
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhard Wunsch
4Institute of Pharmaceutical and Medicinal Chemistry, University of Munster Munster Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Brust
3Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Osama Sabri
1Department of Nuclear Medicine, University of Leipzig Leipzig Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

106

Objectives: The sigma-1 receptor (S1R) acts as a neuromodulator and may play an important role for cognitive and behavioral processes in neuropsychiatric disorders. Cognitive dysfunction is common in unipolar major depressive disorder (MDD). Using S1R-specific (S)-(-)-[18F]Fluspidine PET, the purpose of this study was to investigate the S1R availability and its relationship to depressive and cognitive symptoms in untreated patients with acute early onset MDD (EO-MDD).

Methods: Acute, moderate to severe EO-MDD patients without antidepressive therapy (n = 13; age: 26 ± 6 years; 6 females; age at disease onset: 22 ± 5 years; Hamilton depression rating scale [HAMD-17] 19 ± 4) were investigated and compared with age- and sex-matched healthy controls (HC; n = 12; age: 25 ± 3 years; 6 females [n.s.]) using (S)-(-)-[18F]Fluspidine PET (300 MBq; 0-90 min p.i.; ECAT Exact HR+). Total distribution volumes (VT) were determined using kinetic modeling (2TCM, metabolite correction). Regional VOI-analyses were carried out. Cognitive state (memory, attention, executive function and working memory) was evaluated using the Wechsler memory scale (WMS) and the cognitive screening test PANDA.

Results: In EO-MDD, compared with HC, WMS and PANDA scores were significantly lower indicating cognitive dysfunction (P < 0.05) and (S)-(-)-[18F]Fluspidine VT values were significantly higher especially within the nucleus caudatus, nucleus accumbens, orbitofronto-temporal, anterior cingulate and insular cortices, nucleus raphe and pons (P < 0.01). In EO-MDD, HAMD-17 correlated positively with VT, especially within the anterior and posterior cingulate and occipital cortices and midbrain (R ≥ 0.79; P < 0.01; nuisance WMS/PANDA), however, there were no significant correlations between VT and cognitive dysfunction (P < 0.05; nuisance HAMD-17).

Conclusions: Using (S)-(-)-[18F]Fluspidine PET, we showed an increase of meso-striato-cortico-limbic and paralimbic S1R availability in untreated patients with acute, moderate to severe EO-MDD which was strongly correlated with the degree of depressive symptoms, but not with the cognitive state. These results provide motivation to apply S1R PET to a larger cohort of depressed patients at different disease stages, potentially also in follow-up after therapy initiation.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Relationship between sigma-1 receptor availability and depressive or cognitive symptoms in acute early onset unipolar depression: a (S)-(-)-[18F]Fluspidine PET investigation
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Relationship between sigma-1 receptor availability and depressive or cognitive symptoms in acute early onset unipolar depression: a (S)-(-)-[18F]Fluspidine PET investigation
Philipp Meyer, Maria Strauss, Georg Becker, Swen Hesse, Klara Bednasch, Barbara Ettrich, Franziska Zientek, Michael Rullmann, Julia Luthardt, Steffen Fischer, Marianne Patt, Barthel Henryk, Bernhard Wunsch, Peter Brust, Osama Sabri
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 106;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Relationship between sigma-1 receptor availability and depressive or cognitive symptoms in acute early onset unipolar depression: a (S)-(-)-[18F]Fluspidine PET investigation
Philipp Meyer, Maria Strauss, Georg Becker, Swen Hesse, Klara Bednasch, Barbara Ettrich, Franziska Zientek, Michael Rullmann, Julia Luthardt, Steffen Fischer, Marianne Patt, Barthel Henryk, Bernhard Wunsch, Peter Brust, Osama Sabri
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 106;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
  • Usefulness of99mTc SESTAMIBI Scintigraphy in Persistent Hyperparathyroidism after Kidney Transplant
  • Toll-like receptor 5 in triple-negative breast cancer: a novel reporter for tumor progression
Show more Oral - PhysicianPharm

Advances in Clinical Neuroimaging

  • 18F-MK6240 longitudinal tau PET in ageing and Alzheimer's disease
  • Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma
  • Neuroinflammation in Semantic Variant Primary Progressive Aphasia
Show more Advances in Clinical Neuroimaging

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire